A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers

Authors

Institutions

Publication Details

Journal
BJC Reports
Published
2025-03-26
DOI
https://doi.org/10.1038/s44276-025-00133-6
Citations
3
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
3.14

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers

Mark Lawler, Bryan T. Hennessy, Federica Di Nicolantonio, Francesca Aroldi et al.
3 citations
BJC Reports
Colorectal Cancer Treatments and Studies
3.14
article

A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers

Mark Lawler, Bryan T. Hennessy, Federica Di Nicolantonio, Francesca Aroldi, Ruth Boyd, Corran Roberts, Josep M. Tabernero, Sandra Van Schaeybroeck, Richard Adams, Hajrah Khawaja, Jennifer Houlden, Julien Taı̈eb, Marc Peeters, Élena Elez, Jurgen Del‐Favero, Margaret Grayson, Manuel Salto‐Tellez, Linda Collins, Hans Prenen, Robin L. Jones, Richard H. Wilson, Géraldine Perkins, Robbie Carson, Vlad Popovici, Alberto Bardelli, Karolien Bettens, Vicky M. Coyle, Christian Diego Rolfo, Peter F. Gallagher, Thierry André, Tim Maughan, Pierre Laurent‐Puig, Mark R. Middleton
article en
3 citations

Abstract

No abstract available for this paper.
BJC ReportsVol. 3(1)
Queen's University Belfast (GB), Belfast Health and Social Care Trust (GB), Royal College of Surgeons in Ireland (IE), University of Liverpool (GB), University of Antwerp (BE), Inserm (FR), Université Paris Cité (FR), Masaryk University (CZ), Velindre NHS Trust (GB), Nuffield Orthopaedic Centre (GB), Sorbonne Université (FR), University of Oxford (GB), Centre de Recherche des Cordeliers (FR), Assistance Publique – Hôpitaux de Paris (FR), Agilent Technologies (Belgium) (BE), Antwerp University Hospital (BE), Hôpital Européen Georges-Pompidou (FR), Hôpital Saint-Antoine (FR), IFOM (IT), Université Bourgogne Franche-Comté (FR), Vall d'Hebron Hospital Universitari (ES), Candiolo Cancer Institute (IT), University of Turin (IT), Cardiff University (GB)
Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Merck KGaA, Les Laboratories Pierre Fabre, Seagen, Cancer Research UK, National Institute for Health and Care Research, University of Oxford, European Commission, Queen's University Belfast, Ministerstvo Školství, Mládeže a Tělovýchovy, Queen's University, Associazione Italiana per la Ricerca sul Cancro, Servier, Aptitude Health, Genentech, Samsung, Chugai Pharmaceutical, Takeda Oncology, RECETOX Přírodovědecké Fakulty Masarykovy Univerzity, Daiichi Sankyo Europe, FP7 Health
Good health and well-being
Openalex Percentile: Top 9%
Colorectal Cancer Treatments and Studies
3.14
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.